Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study (Q100725420)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

title

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

17

David J Pinato

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

author name string

Saur Hajiev

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Elias Allara

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Leila Motedayеn-Aval

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Tadaaki Arizumi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Dominik Bettinger

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Mario Pirisi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Lorenza Rimassa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Tiziana Pressiani

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Nicola Personeni

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Laura Giordano

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Masatoshi Kudo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Robert Thimme

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Joong-Won Park

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Tamar H Taddei

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

David E Kaplan

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

Ramya Ramaswami

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

22 October 2020

publication date

19 October 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

British Journal of Cancer

22 October 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33071284 AND SRC:MED&resulttype=core&format=json

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

22 October 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Updated treatment approach to hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Management of hepatocellular carcinoma in the elderly

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Epidemiology of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age.

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Imputing missing covariate values for the Cox model

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Older Patients (Still) Left Out of Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Hepatocellular carcinoma in elderly patients: challenges and solutions

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

How do oncologists make decisions about chemotherapy for their older patients with cancer? A survey of Australian oncologists

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021

Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41416-020-01116-9

7 January 2021